

CITATION REPORT

List of articles citing

Inhibition of terfenadine metabolism. Pharmacokinetic and pharmacodynamic consequences

DOI: 10.2165/00003088-199427010-00001
Clinical Pharmacokinetics, 1994, 27, 1-5.

Source: <https://exaly.com/paper-pdf/25418525/citation-report.pdf>

Version: 2024-04-25

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
67	The role of human cytochrome P450 enzymes in the metabolism of anticancer agents: implications for drug interactions. <i>British Journal of Clinical Pharmacology</i> , 1995 , 40, 523-30	3.8	224
66	Pharmacokinetic-pharmacodynamic relationships of H1-antihistamines. <i>Clinical Pharmacokinetics</i> , 1995 , 28, 419-32	6.2	30
65	A risk-benefit assessment of drugs used in the management of obsessive-compulsive disorder. <i>Drug Safety</i> , 1996 , 15, 116-34	5.1	11
64	Itraconazole. A reappraisal of its pharmacological properties and therapeutic use in the management of superficial fungal infections. <i>Drugs</i> , 1996 , 51, 585-620	12.1	119
63	Cardiac Arrest Associated with Combination Cisapride and Itraconazole Therapy. <i>Journal of Cardiovascular Pharmacology and Therapeutics</i> , 1996 , 1, 255-258	2.6	23
62	The influence of food on the absorption and metabolism of drugs: an update. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 1996 , 21, 201-11	2.7	39
61	Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. <i>Clinical Pharmacology and Therapeutics</i> , 1996 , 59, 383-8	6.1	143
60	An Overview of Current Cytochrome P450 Technology for Assessing the Safety and Efficacy of New Materials. <i>Toxicologic Pathology</i> , 1996 , 24, 45-57	2.1	129
59	Contribution of a liaison clinical pharmacist to an inpatient palliative care unit. <i>Palliative Medicine</i> , 1997 , 11, 209-16	5.5	24
58	Role of cytochrome P450 enzymes in drug-drug interactions. <i>Advances in Pharmacology</i> , 1997 , 43, 7-35	5.7	211
57	The use of other drugs to allow a lower dosage of cyclosporin to be used. Therapeutic and pharmacoeconomic considerations. <i>Clinical Pharmacokinetics</i> , 1997 , 32, 357-67	6.2	42
56	Human liver cytochrome P450 enzymes involved in the 7-hydroxylation of R- and S-warfarin enantiomers. <i>Biochemical Pharmacology</i> , 1997 , 54, 1195-203	6	119
55	Drug-drug interactions: effect of quinidine on nifedipine binding to human cytochrome P450 3A4. <i>Biochemical Pharmacology</i> , 1997 , 53, 455-60	6	50
54	Oral antifungal drug interactions. <i>Dermatologic Clinics</i> , 1997 , 15, 535-44	4.2	26
53	In vitro and in vivo drug interactions involving human CYP3A. <i>Annual Review of Pharmacology and Toxicology</i> , 1998 , 38, 389-430	17.9	709
52	Systemic antifungal agents. Drug interactions of clinical significance. <i>Drug Safety</i> , 1998 , 18, 83-97	5.1	181
51	Current issues in onychomycosis. <i>Annals of Pharmacotherapy</i> , 1998 , 32, 204-14	2.9	13

50	Clinically important pharmacokinetic drug-drug interactions: role of cytochrome P450 enzymes. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 1998 , 23, 403-16	2.2	132
49	Update on drug interactions with azole antifungal agents. <i>Annals of Pharmacotherapy</i> , 1998 , 32, 915-28	2.9	64
48	Adverse drug interactions in dental practice: interactions involving antibiotics. Part II of a series. <i>Journal of the American Dental Association</i> , 1999 , 130, 236-51	1.9	40
47	Lack of effect of terfenadine on the pharmacokinetics of the CYP3A4 substrate buspirone. <i>Basic and Clinical Pharmacology and Toxicology</i> , 1999 , 84, 165-9		7
46	Interplay between CYP3A-mediated metabolism and polarized efflux of terfenadine and its metabolites in intestinal epithelial Caco-2 (TC7) cell monolayers. <i>Pharmaceutical Research</i> , 1999 , 16, 625-32	4.5	52
45	Drug interactions with itraconazole, fluconazole, and terbinafine and their management. <i>Journal of the American Academy of Dermatology</i> , 1999 , 41, 237-49	4.5	73
44	Rat pregnane X receptor: molecular cloning, tissue distribution, and xenobiotic regulation. <i>Archives of Biochemistry and Biophysics</i> , 1999 , 368, 14-22	4.1	170
43	Lack of effect of erythromycin and ketoconazole on the pharmacokinetics and pharmacodynamics of steady-state intranasal levocabastine. <i>Journal of Clinical Pharmacology</i> , 1999 , 39, 76-85	2.9	9
42	Pharmacogenomics of cytochrome P450 and other enzymes involved in biotransformation of xenobiotics. <i>Drug Development Research</i> , 2000 , 49, 4-16	5.1	28
41	Macrolide - induced clinically relevant drug interactions with cytochrome P-450A (CYP) 3A4: an update focused on clarithromycin, azithromycin and dirithromycin. <i>British Journal of Clinical Pharmacology</i> , 2000 , 50, 285-95	3.8	134
40	Analysis of hydroxylated and N-dealkylated metabolites of terfenadine in microsomal incubates by liquid chromatography--mass spectrometry. <i>Biomedical Applications</i> , 2000 , 741, 145-53		5
39	Hepatic disposition of fexofenadine: influence of the transport inhibitors erythromycin and dibromosulphothalein. <i>Pharmaceutical Research</i> , 2000 , 17, 1511-5	4.5	30
38	Effects of imidazole antimycotics on the liver microsomal cytochrome P450 isoforms in rats: comparison of in vitro and ex vivo studies. <i>European Journal of Drug Metabolism and Pharmacokinetics</i> , 2000 , 25, 121-6	2.7	21
37	Effects of the antifungal agents on oxidative drug metabolism: clinical relevance. <i>Clinical Pharmacokinetics</i> , 2000 , 38, 111-80	6.2	396
36	Common and uncommon cytochrome P450 reactions related to metabolism and chemical toxicity. <i>Chemical Research in Toxicology</i> , 2001 , 14, 611-50	4	1303
35	Systemic antifungal therapy. <i>Dermatologic Clinics</i> , 2001 , 19, 35-52	4.2	16
34	The integration of four major determinants of antibiotic action: bactericidal activity, postantibiotic effect, susceptibility, and pharmacokinetics. <i>Journal of Chemotherapy</i> , 2002 , 14, 579-83	2.3	11
33	Drug interactions in dentistry: the importance of knowing your CYPs. <i>Journal of the American Dental Association</i> , 2004 , 135, 298-311	1.9	49

32	Herbal interactions involving cytochrome p450 enzymes: a mini review. <i>Toxicological Reviews</i> , 2004 , 23, 239-49		102
31	Human Cytochrome P450 Enzymes. 2005 , 377-530		189
30	Cytochrome P450s and other enzymes in drug metabolism and toxicity. <i>AAPS Journal</i> , 2006 , 8, E101-11	3.7	421
29	Cytochrome P450 enzymes in drug metabolism and chemical toxicology: An introduction. <i>Biochemistry and Molecular Biology Education</i> , 2006 , 34, 66-74	1.3	107
28	Antidepressant-drug interactions are potentially but rarely clinically significant. <i>Neuropsychopharmacology</i> , 2006 , 31, 1594-604; discussion 1614-5	8.7	27
27	Reduction of site-specific CYP3A-mediated metabolism for dual angiotensin and endothelin receptor antagonists in various in vitro systems and in cynomolgus monkeys. <i>Drug Metabolism and Disposition</i> , 2007 , 35, 795-805	4	14
26	Pharmacokinetic drug interactions involving 17alpha-ethinylestradiol: a new look at an old drug. <i>Clinical Pharmacokinetics</i> , 2007 , 46, 133-57	6.2	127
25	Applying mechanisms of chemical toxicity to predict drug safety. <i>Chemical Research in Toxicology</i> , 2007 , 20, 344-69	4	197
24	Mechanisms of pharmacokinetic and pharmacodynamic drug interactions associated with ritonavir-enhanced tipranavir. <i>Pharmacotherapy</i> , 2007 , 27, 888-909	5.8	36
23	Toxicological significance of mechanism-based inactivation of cytochrome p450 enzymes by drugs. <i>Critical Reviews in Toxicology</i> , 2007 , 37, 389-412	5.7	64
22	Cytochrome p450 and chemical toxicology. <i>Chemical Research in Toxicology</i> , 2008 , 21, 70-83	4	1124
21	Adverse drug interactions in dentistry. <i>Periodontology 2000</i> , 2008 , 46, 109-42	12.9	32
20	Role of cytochrome P450 in drug interactions. <i>Nutrition and Metabolism</i> , 2008 , 5, 27	4.6	92
19	Cytochrome P450: Structure, Function, and Application in Drug Discovery and Development. 55-107		
18	The biochemistry of drug metabolism--an introduction: part 7. Intra-individual factors affecting drug metabolism. <i>Chemistry and Biodiversity</i> , 2009 , 6, 1477-660, table of contents	2.5	24
17	Updates on cytochrome P450-mediated cardiovascular drug interactions. <i>American Journal of Therapeutics</i> , 2009 , 16, 155-63	1	11
16	Cytochrome P450 Enzymes. 2010 , 41-76		4
15	Updates on cytochrome p450-mediated cardiovascular drug interactions. <i>Disease-a-Month</i> , 2010 , 56, 163-79	4.4	9

14	Liver Drug Metabolism. 2011 , 127-144		1
13	Cytochrome P450-Mediated Drug Interaction and Cardiovascular Safety: The Seldane to Allegra Transformation. 2014 , 523-534		3
12	Pharmacokinetic evaluation of C-3 modified 1,8-naphthyridine-3-carboxamide derivatives with potent anticancer activity: lead finding. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2014 , 29, 710-21	5.6	8
11	Human Cytochrome P450 Enzymes. 2015 , 523-785		60
10	Cytochrome P450 Enzymes. 2018 , 54-86		3
9	Systematic Evolution of Decoy Molecules for the Highly Efficient Hydroxylation of Benzene and Small Alkanes Catalyzed by Wild-Type Cytochrome P450BM3. <i>ACS Catalysis</i> , 2020 , 10, 9136-9144	13.1	6
8	A history of the roles of cytochrome P450 enzymes in the toxicity of drugs. <i>Toxicological Research</i> , 2020 , 37, 1-23	3.7	25
7	Update: Clinically Significant Cytochrome P-450 Drug Interactions. 1998 , 18, 84-112		124
6	The safety assessment of over-the-counter (OTC) products. <i>Archives of Toxicology Supplement</i> , 1995 , 17, 305-11		7
5	Inhibition of terfenadine metabolism in vitro by azole antifungal agents and by selective serotonin reuptake inhibitor antidepressants: relation to pharmacokinetic interactions in vivo. <i>Journal of Clinical Psychopharmacology</i> , 1996 , 16, 104-12	1.7	63
4	Antibiotic exposure and its relationship to postantibiotic effect and bactericidal activity: constant versus exponentially decreasing tobramycin concentrations against <i>Pseudomonas aeruginosa</i> . <i>Antimicrobial Agents and Chemotherapy</i> , 1997 , 41, 1808-11	5.9	5
3	Inhibition of Drug Metabolizing Enzymes. 1999 , 203-227		10
2	Toxicogenomics and pharmacogenomics. 2002 ,		
1	Drug Interactions with Agents Used in Respiratory Disease. 1997 , 233-277		